http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110025717-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-333 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P33-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01021 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-8964 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-8964 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 |
| filingDate | 2019-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110025717-B |
| titleOfInvention | Application of timosaponin enzymatic hydrolysate in preparation of medicines for inhibiting skin superficial fungi |
| abstract | The invention provides an application of an anemarrhena saponin enzymatic hydrolysis converted substance in preparation of a medicament for inhibiting skin superficial fungi. In the application provided by the invention, the preparation of the timosaponin enzymatic conversion product comprises the following steps: performing enzymolysis conversion on the rhizoma anemarrhenae extract by using beta-glucosidase to obtain a timosaponin enzymatic conversion product. In the invention, the converted product of the timosaponin enzymolysis is used as an active pharmaceutical ingredient for inhibiting skin superficial fungi, the minimum inhibitory concentration of the converted product to the fungi is 4 mug/ml, the bacteriostatic ability is obviously superior to that of the total timosaponin, and the converted product has a certain application prospect in the aspect of treating skin superficial fungal diseases. |
| priorityDate | 2019-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.